The EPS projection of Epizyme, Inc. (NASDAQ:EPZM) for quarter ended 2016-09-30 is $-0.55. A week before, the EPS forecast was $-0.55 against target of $-0.55, a month earlier. This estimate stood at $-0.55 60 days earlier versus forecast of $-0.55 90 days earlier, confirming a deviation of 0%.
Epizyme, Inc. (NASDAQ:EPZM) reported that 18 days ago, the positive EPS revisions were 1 and negative revisions at 0.
In last week, the per-share earnings was lowered 0 times and 0 times positively. In last 120, 60, 30 and 90 days the positive revisions were 2, 2, 0 and 2, respectively.
The downgrade of EPS estimates for Epizyme, Inc. (NASDAQ:EPZM) in the preceding 120, 60, 30 and 90 days were 0, 1, 0 and 1, in that order.
As per the latest update, for the quarter closed 1, the EPS estimate of Epizyme, Inc. (NASDAQ:EPZM) was $-0.55. This projection was computed after accounting 4 calls. As reported on 2016-05-09 the EPS was $-0.41. The change was $0.07, demonstrating a percentage deviation of 14.58%. The projections confirmed a standard deviation of 0.05.
Quarterly Sales Estimates
For the fiscal 2016, the yearly sales target for Epizyme, Inc. (NASDAQ:EPZM) stands at $0.648 and the median estimate at $0.5. Almost 4 analysts announced their estimates.
The highest estimate is $1.12 while the lowest target is $0.472 showing standard deviation of 0.314%.
As many as 4 analysts released sales estimates reised in upside while 4 reduced sales estimates, demonstrating a deviation of 0%.
In last month, 4 revised sales number projection on upside while 4 lowered the sales target, demonstrating a deviation of 0%.
A quarter ago, 4 hiked sales estimations and 4 reduced sales forecast. Epizyme, Inc. (NASDAQ:EPZM) stated that the change in forecast was -23.674%.
1 Chart Pattern Every Investor Should Know
This little-known pattern preceded moves of 578% in ARWR, 562% in LCI, 513% in ICPT, 439% in EGRX, 408% in ADDUS and more...